Innate Pharma S.A. (OTCMKTS:IPHYF) Sees Significant Decrease in Short Interest

Innate Pharma S.A. (OTCMKTS:IPHYF) saw a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 500 shares, a drop of 94.0% from the December 15th total of 8,400 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 5.0 days.

Innate Pharma Stock Performance

IPHYF remained flat at $2.90 during trading on Wednesday. Innate Pharma has a 1-year low of $1.28 and a 1-year high of $2.90. The stock’s 50 day moving average is $2.11 and its 200-day moving average is $2.15.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.